VYNE Therapeutics第三季度每股收益$（0.17）错过$（0.13）估计，销售额为169，000万美元，超过100，000万美元估计

VYNE Therapeutics (NASDAQ: VYNE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 41.38 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $169.000 thousand which beat the analyst consensus estimate of $100.000 thousand by 69.00 percent. This is a 39.67 percent increase over sales of $121.000 thousand the same period last year.